Endocrine Abstracts

The prostate specific membrane antigen (PSMA) has been reported to be selectively overexpressed in the tumor-associated neovasculature of a wide variety of solid tumors including breast carcinoma, and growth and progression of breast cancers are accompanied by increased neovascularization (angiogenesis). In this context, the robust expression of PSMA by breast cancer lesions as evidenced using PSMA-PET/CT makes PSMA an interesting potential target for antiangiogenic therapy of breast carcinoma. Furthermore, the 68Ga-PSMA avid lesions encourage ongoing exploration about the potential therapeutic application of PSMA-targeted radioligand therapy (PSMA-RLT) against breast cancer. PSMA can be probably be seen as one of the most interesting molecular imaging and therapeutic probe that may provide new opportunities in the design of individually suited therapies and response evaluation.